| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/12/2003 | CA2456077A1 Individualized anti-cancer antibodies |
| 09/12/2003 | CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 09/11/2003 | WO2003074500A2 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors |
| 09/11/2003 | WO2003074449A2 Multi-substitued selective androgen receptor modulators and methods of use thereof |
| 09/11/2003 | WO2003073995A2 Dna vaccine against proliferating endothelial cells and methods of use thereof. |
| 09/11/2003 | US20030171579 N-benzyl-N'-phenylurea derivatives; inhibitors of the coagulation factors Xa and VIIa |
| 09/11/2003 | US20030171566 An isolated human nucleic acid encoding a nevoid basal cell carcinoma syndrome protein, antibodies, detecting tumor protein, therapeutic treatment of tumor, cancer; genetic engineering |
| 09/11/2003 | US20030171556 Diagnosis and therapeutic treatment of Alzheimer's Disease; drug screening |
| 09/11/2003 | US20030171552 A single-chain T-cell receptor covalently linked to single-chain antibody; anticarcinogenic agents for treating cancer |
| 09/11/2003 | US20030171548 Immunoreactive proteins where the percentage of immuno-reactive molecules as determined in a modified Lindmo-test is >81%; fermentation of culture of fluidized reactor; diagnosis of inflammatory and bone marrow displacing process |
| 09/11/2003 | US20030171546 Chimeric immunoreceptor useful in treating human cancers |
| 09/11/2003 | US20030171537 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| 09/11/2003 | US20030171430 Dissolving in iodinated poppyseed oil fatty ester |
| 09/11/2003 | US20030171429 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues |
| 09/11/2003 | US20030171416 Nordihydroguaiaretic acid; anticancer agents, viricides |
| 09/11/2003 | US20030171415 Strokes; cardiovascular disorders; mixture of melmisartan and ramipril |
| 09/11/2003 | US20030171409 Novel delta dicarbonyl compounds and methods for using the same |
| 09/11/2003 | US20030171404 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 09/11/2003 | US20030171400 Rheumatic diseases; osteoporosis; multiple sclerosis; autoimmune disease; joint replacements |
| 09/11/2003 | US20030171389 Anticancer agents; bone disorders; antiarthritic agents |
| 09/11/2003 | US20030171386 Small molecules for the treatment of abnormal cell growth |
| 09/11/2003 | US20030171384 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 09/11/2003 | US20030171378 Indolinone derivatives |
| 09/11/2003 | US20030171364 Phosphodiesterase inhibitor compounds; therapeutic activity as anti-inflammatory and anti-allergic medicinal products, and in the treatment of various respiratory diseases such as asthma |
| 09/11/2003 | US20030171359 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases |
| 09/11/2003 | US20030171357 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/11/2003 | US20030171356 Methods for alzheimer's disease treatment and cognitive enhancement |
| 09/11/2003 | US20030171354 Indole derivatives |
| 09/11/2003 | US20030171342 Novel 16-ene-C25-oxime and 16-ene- C-25-oxime ether analogs of 1 alpha ,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. |
| 09/11/2003 | US20030171339 Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds |
| 09/11/2003 | US20030171337 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and |
| 09/11/2003 | US20030171334 Treatment of prostate cancer |
| 09/11/2003 | US20030171333 Pharmaceutical composition containing at least a polymer combined with or conjugated to at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof |
| 09/11/2003 | US20030171329 Stable compositions comprising tezacitabine |
| 09/11/2003 | US20030171324 Reagents which bind to human DESC1-like serine protease gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to cancer, chronic obstructive pulmonary disease (COPD), |
| 09/11/2003 | US20030171305 Tetraphenylbacteriochlorin derivatives and compositions containing the same |
| 09/11/2003 | US20030171304 Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof |
| 09/11/2003 | US20030171296 Pharmaceutical formulations for sustained drug delivery |
| 09/11/2003 | US20030171289 Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 09/11/2003 | US20030171280 Compositions and methods for modulation of immune responses |
| 09/11/2003 | US20030171278 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 09/11/2003 | US20030171273 DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the beta -globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. |
| 09/11/2003 | US20030171271 Therapeutic application in the treatment of conditions including cancer, macular degeneration and retinopathies. Also included are methods of treating a patient having a pathological condition characterized by an increase in |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030171261 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer |
| 09/11/2003 | US20030171255 Modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), |
| 09/11/2003 | US20030170895 Methods of making hypermutable cells using PMSR homologs |
| 09/11/2003 | US20030170893 Nanocapsule encapsulation system and method |
| 09/11/2003 | US20030170859 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders |
| 09/11/2003 | US20030170854 Recombinant human creatine kinase heterodimer with solution-stability |
| 09/11/2003 | US20030170839 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/11/2003 | US20030170838 Novel polynucleotides and polypeptides encoded thereby |
| 09/11/2003 | US20030170828 Synthesis of complex carbohydrates |
| 09/11/2003 | US20030170812 Interleukin-1beta converting enzyme like cysteine protease |
| 09/11/2003 | US20030170792 MAGE-3 peptides presented by HLA class ll molecules |
| 09/11/2003 | US20030170785 CDNA encoding the human alpha2 delta4 calcium channel subunit |
| 09/11/2003 | US20030170754 Anticancer agents; diagnosis of prostate cancer |
| 09/11/2003 | US20030170746 Method for screening an agent for ability to inhibit heparanase activity |
| 09/11/2003 | US20030170730 Testing for drug desistance of cancer drugs |
| 09/11/2003 | US20030170648 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression |
| 09/11/2003 | US20030170628 Forsenic analysis; medical diagnosis; chromosome markers |
| 09/11/2003 | US20030170320 Extract is composed of carboxy alkyl esters, especially quinic acid lactone. |
| 09/11/2003 | US20030170319 Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 09/11/2003 | US20030170315 Bioactivation of iron salt, especially an ferric ferrous salt, by adding a magnesium salt (MgCl2); useful as a medicine to treat diseases such as diabetes, freshness preservative agent, and animal and plant growth promoter |
| 09/11/2003 | US20030170300 Combination chemotherapy |
| 09/11/2003 | US20030170299 Therapeutic methods for acute myeloid leukemia |
| 09/11/2003 | US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin |
| 09/11/2003 | US20030170292 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 09/11/2003 | US20030170286 Codrug with at least two constituent moieties cleavably linked covalently to one another; dimensioned to position two radiation seeds a predetermined distance apart. |
| 09/11/2003 | US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen |
| 09/11/2003 | US20030170268 Administering a fusion protein of a heat shock protein or immunostimulatory fragment and a human papilloma virus protein or an antigenic fragment; or a nucleic acid coding the fusion protein |
| 09/11/2003 | US20030170256 Coding for antigens expressed by tumor cells which may be recognized by cytotoxic T cells, leading to lysis of the tumor that express it. |
| 09/11/2003 | US20030170253 Useful in stimulating angiogenesis as well as in diagnostic applications. |
| 09/11/2003 | US20030170243 Use of human plasma hyaluronidase in cancer treatment |
| 09/11/2003 | US20030170235 Treatment with anti-ErbB2 antibodies |
| 09/11/2003 | US20030170234 Combination of the antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin; treating cancer |
| 09/11/2003 | US20030170233 Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody |
| 09/11/2003 | US20030170220 For inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia |
| 09/11/2003 | US20030170217 Bifidobacterium in the treatment of inflammatory disease |
| 09/11/2003 | US20030170216 SYN3 compositions and methods |
| 09/11/2003 | US20030170211 For delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to be expressed in the animal or the animal cells |
| 09/11/2003 | US20030170178 For therapy and diagnosis of infectious diseases; diseases characterised by cellular hyperproliferation such as tumours, psoriasis, actinic keratosis, atheromas, endoarterial hyperplasia, prostate hyperplasia; for sterilization of blood |
| 09/11/2003 | US20030170174 For therapy of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation; contrast agents |
| 09/11/2003 | US20030167999 Crystal |
| 09/10/2003 | EP1343013A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents. |
| 09/10/2003 | EP1342729A2 Antibodies and antisense molecules for G-coupled receptor showing selective affinity for ATP |
| 09/10/2003 | EP1342728A1 Radiosensitivity enhancers in radiotherapy for cancer and nucleic acids and proteins enhancing radiosensitivity |
| 09/10/2003 | EP1342719A1 Benzodiazepine derivatives useful as CCK-Receptor Antagonists |
| 09/10/2003 | EP1342477A1 Cationic vehicle: dna complexes and their use in gene therapy |
| 09/10/2003 | EP1342476A2 FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours |
| 09/10/2003 | EP1342085A2 Non-apoptotic forms of cell death and methods of modulation |
| 09/10/2003 | EP1341928A2 Methods and kits for detecting protein kinases |
| 09/10/2003 | EP1341923A2 Methods for enhancing the efficacy of cancer therapy |
| 09/10/2003 | EP1341921A2 Hydrolases |
| 09/10/2003 | EP1341920A2 Human elongase genes and uses thereof |
| 09/10/2003 | EP1341918A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/10/2003 | EP1341914A2 Regulation of angiogenesis with zinc finger proteins |
| 09/10/2003 | EP1341908A2 Targeted enzyme prodrug therapy |
| 09/10/2003 | EP1341907A2 Target enzymes |
| 09/10/2003 | EP1341817A2 Tff peptides |